NCT00097500 - Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide

subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets

DRUG

Insulin glargine

subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets

DRUG

Metformin

Patients usual dosage

Trial Locations (3)

Research Site, Helsinki

Research Site, Amsterdam

Research Site, Gothenburg